1. Academic Validation
  2. Diverse heterocyclic scaffolds as allosteric inhibitors of AKT

Diverse heterocyclic scaffolds as allosteric inhibitors of AKT

  • J Med Chem. 2012 Feb 9;55(3):1261-73. doi: 10.1021/jm201394e.
Jason G Kettle 1 Simon Brown Claire Crafter Barry R Davies Phillippa Dudley Gary Fairley Paul Faulder Shaun Fillery Hannah Greenwood Janet Hawkins Michael James Keith Johnson Clare D Lane Martin Pass Jennifer H Pink Helen Plant Sabina C Cosulich
Affiliations

Affiliation

  • 1 Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, United Kingdom. jason.kettle@astrazeneca.com
Abstract

Wide-ranging exploration of potential replacements for a quinoline-based inhibitor of activation of Akt kinase led to number of alternative, novel scaffolds with potentially improved potency and physicochemical properties. Examples showed predictable DMPK properties, and one such compound demonstrated pharmacodynamic knockdown of phosphorylation of Akt and downstream biomarkers in vivo and inhibition of tumor growth in a breast Cancer xenograft model.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-18296
    98.41%, Akt Inhibitor
    Akt